News

NIH-led effort – including ISB – launches Big Data portal for Alzheimer’s drug discovery

The National Institutes of Health announced the launch of a new Alzheimer’s Big Data portal, which includes the first wave of data for use by the research community. This portal is the result of the Accelerating Medicines Partnership (AMP) program, which focuses on facilitating collaboration among government agencies, academia and industry in order to translate research more quickly to therapies.

The launch of the AMP Alzeheimers Disease Knowledge Portal is the first major release of the project, to which a consortium of teams contribute data and analysis: Eric Schadt, Ph.D., Icahn School of Medicine at Mount Sinai, New York; Philip De Jager, M.D., Ph.D., Eli and Edythe L. Broad Institute of MIT and Harvard, Boston; Todd Golde, M.D., Ph.D., University of Florida, Gainesville; and Alan Levey, M.D., Ph.D., Emory University, Atlanta. Researchers from Rush University, Chicago; Mayo Clinic, Jacksonville, Fla.; Institute for Systems Biology, Seattle; the University of California, Los Angeles and a number of other academic centers are also participating. ISB’s Price Lab is participating in this project through a collaboration with the University of Florida.

Ben Heavner, a research scientist in the Price Lab, is leading the bioinformatics work, which involves translating raw data into a uniform format and then uploading to the data portal. “This is a huge step for open science,” Ben said. “This portal offers access to thousands of data sets pre-publication so that all researchers have the opportunity to make the discoveries that will lead to better therapeutics .”

Read more about the NIH’s $45M in grants to support Alzheimer’s research.

Recent Articles

  • How Old Are You? Your Body Might Disagree With That Answer

    Researchers at ISB harnessed deep molecular and physiological information to determine an individual’s biological age, which they found was reflective of overall health compared to chronological age. The findings were published in the Journals of Gerontology: Series A.

  • Using Blood to Predict Gut Microbiome Diversity

    Predicting the alpha diversity of an individual’s gut microbiome is possible by examining metabolites in the blood. The robust relationship between host metabolome and gut microbiome diversity opens the door for a fast, cheap and reliable blood test to identify individuals with low gut diversity.

  • Town Hall Seattle panel

    Expert Panel Discusses 21st Century Health at Town Hall Seattle Event

    In a public panel discussion put on by Town Hall Seattle and ISB, legendary biologist Dr. Lee Hood, PSJH Chief Clinical Officer Dr. Amy Compton-Phillips, and PATH’s Program Leader of Diagnostics Tala de los Santos addressed the promise — and challenges — of implementing and practicing 21st century health care.